Management of Hepatocellular Carcinoma with Portal Vein Thrombosis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Apr 3

PMID 25834310

Citations 59

Authors

Matthew Quirk

Yun Hwan Kim

Sammy Saab

Edward Wolfgang Lee

Affiliations

Soon will be listed here.

Abstract

Management of hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) is complex and requires an understanding of multiple therapeutic options. PVT is present in 10%-40% of HCC at the time of diagnosis, and is an adverse prognostic factor. Management options are limited, as transplantation is generally contraindicated, and surgical resection is only rarely performed in select centers. Systemic medical therapy with sorafenib has been shown to modestly prolong survival. Transarterial chemoembolization has been performed in select cases but has shown a high incidence of complications. Emerging data on treatment of PVT with Y-90 radioembolization suggest that this modality is well-tolerated and associated with favorable overall survival. Current society guidelines do not yet specifically recommend radioembolization for patients with PVT, but this may change with the development of newer staging systems and treatment algorithms. In this comprehensive literature review, we present current and available management options with the relative advantages, disadvantages and contraindications of these treatment options with summarized data on overall survival.

Citing Articles

Malignant Portal Vein Thrombosis in Adenosquamous Carcinoma of the Gall Bladder.

Pulappadi V, Rangarajan K, Kumar S Cureus. 2025; 16(12):e75790.

PMID: 39822406 PMC: 11735235. DOI: 10.7759/cureus.75790.

Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150.

Finn R, Galle P, Ducreux M, Cheng A, Reilly N, Nicholas A Liver Cancer. 2024; 13(6):655-668.

PMID: 39687036 PMC: 11649257. DOI: 10.1159/000539897.

The Imbalance of Homeostasis in Neutrophil Extracellular Traps is Associated with Portal Vein Thrombosis in Patients with Decompensated Cirrhosis.

Han M, Liu Y, Cao Y, Zhang Y, Yan Y, Deng S J Clin Transl Hepatol. 2024; 12(12):1009-1019.

PMID: 39649033 PMC: 11622206. DOI: 10.14218/JCTH.2024.00165.

The Molecular Mechanisms of Portal Vein Thrombosis in Hepatocellular Carcinoma.

Galasso L, Cerrito L, Termite F, Mignini I, Esposto G, Borriello R Cancers (Basel). 2024; 16(19).

PMID: 39409869 PMC: 11482560. DOI: 10.3390/cancers16193247.

The State of Systematic Therapies in Clinic for Hepatobiliary Cancers.

Chen W, Hu Z, Li G, Zhang L, Li T J Hepatocell Carcinoma. 2024; 11:629-649.

PMID: 38559555 PMC: 10981875. DOI: 10.2147/JHC.S454666.

References

Kulik L, Carr B, Mulcahy M, Lewandowski R, Atassi B, Ryu R . Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2007; 47(1):71-81. DOI: 10.1002/hep.21980. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Lencioni R, Kudo M, Ye S, Bronowicki J, Chen X, Dagher L . First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012; 66(7):675-83. DOI: 10.1111/j.1742-1241.2012.02940.x. View

Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S . Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011; 54(3):868-78. DOI: 10.1002/hep.24451. View

Lazo M, Hernaez R, Eberhardt M, Bonekamp S, Kamel I, Guallar E . Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013; 178(1):38-45. PMC: 3698993. DOI: 10.1093/aje/kws448. View

Forner A, Reig M, Rodriguez de Lope C, Bruix J . Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010; 30(1):61-74. DOI: 10.1055/s-0030-1247133. View

Dawson L, Ten Haken R . Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005; 15(4):279-83. DOI: 10.1016/j.semradonc.2005.04.005. View

Dai Q, Gu H, Ye S, Zhang Y, Lin X, Lau W . Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol Clin Oncol. 2014; 2(6):1047-1054. PMC: 4179804. DOI: 10.3892/mco.2014.391. View

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

10.

Llovet J, Bustamante J, Castells A, Vilana R, Ayuso M, Sala M . Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1998; 29(1):62-7. DOI: 10.1002/hep.510290145. View

11.

Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

12.

Jeong S, Jang J, Shim K, Lee S, Kim S, Cha S . Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. Gut Liver. 2013; 7(6):696-703. PMC: 3848540. DOI: 10.5009/gnl.2013.7.6.696. View

13.

Chevret S, Trinchet J, Mathieu D, Rached A, Beaugrand M, Chastang C . A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol. 1999; 31(1):133-41. DOI: 10.1016/s0168-8278(99)80173-1. View

14.

Sato K, Lewandowski R, Bui J, Omary R, Hunter R, Kulik L . Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006; 29(4):522-9. DOI: 10.1007/s00270-005-0171-4. View

15.

Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A . General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol. 2010; 34(3):337-41. DOI: 10.1097/COC.0b013e3181ec61bb. View

16.

Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme M, Bouattour M . Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2010; 22(9):1106-10. DOI: 10.1097/MEG.0b013e3283386053. View

17.

Chen X, Qiu F, Wu Z, Zhang Z, Huang Z, Chen Y . Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol. 2006; 13(7):940-6. DOI: 10.1245/ASO.2006.08.007. View

18.

Lee H, Kim J, Choi I, Chung J, Park J, Kim C . The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer. 1997; 79(11):2087-94. View

19.

Lau W, Sangro B, Chen P, Cheng S, Chow P, Lee R . Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013; 84(5):311-8. DOI: 10.1159/000348325. View

20.

Park M, Kim S, Park J, Kim D, Ahn S, Han K . Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol. 2012; 71(1):165-73. DOI: 10.1007/s00280-012-1993-9. View